US FDA’s Elsa AI Platform Is Not Guiding Regulatory Decisions, Official Says

Tala Fakhouri said the agency’s use of the AI tool in the review process has generated lots of questions.

AI will not have a hand in drug approval decisions, an FDA official said. (Shutterstock)
Key Takeaways
  • The FDA will not use its Elsa AI platform to make decisions on drug approvals, Tala Fakhouri told the DIA Global Annual Meeting.

The US Food and Drug Administration is not using its Elsa generative artificial intelligence tool for regulatory decisions, associate director...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from AI

Australia Targets Clinical Trial Reform, AI Use And Drug Shortages In 12-Month Plan

 

Reforming clinical trial regulations, addressing the use of artificial intelligence, mitigating medicines shortages and strengthening ties with other drug regulators are key priorities for Australia’s Therapeutic Goods Administration over the next year.

Report Shows Extent Of AI Use In EU Medicines Regulation During 2024

 

The AI observatory, created by the European medicines regulatory network to track the evolving use of artificial intelligence in medicines development and regulation, has issued its first annual report.

Beijing City Releases AI Action Plan Including Drug Regulation

 
• By 

Amid the wait for an action plan to apply AI tools to drug regulation at the national level in China, capital city Beijing has released its own vision of scenarios for the technology in the healthcare sector.

ANDA User Fees: Complex Generics, Transparency, Communications Are Early Negotiation Targets

 
• By 

Teva seeks a dedicated development program and first-cycle approval metrics for complex generics. Role of artificial intelligence in the generic drug review process is a talking point for both agency and industry at reauthorization kickoff meeting.

More from Pink Sheet

Danish Medicines Agency Wants Companies To Use “Better Data Format” To Submit Bioequivalence Studies

 

The Danish Medicines Agency is requesting that data from bioequivalence studies to be submitted in the CDISC format in addition to the current eCTD format. It believes the move will make it easier for the agency claims to access and analyze data and will reduce the burden for applicants.

England’s NICE Hunts For New Chief As Sam Roberts Prepares To Step Down

 

Sam Roberts, chief executive of the health technology assessment institute, NICE, will step down from her role at the end of the year. The agency is now on the lookout for a new leader, who will be the fourth in its history.

NDA User Fees Will Grow 8.6% Next Year As FDA Projects More Applications But Fewer Sponsor Meetings

 

The ups – and some downs – of the US FDA’s prescription, biosimilar, and generic user fees for FY 2026 are tabulated by the Pink Sheet.